HIV Protease: Viral Lifecycle Role and Protease Inhibitor Therapeutics
HIV-1 protease (PR) is a 99-amino-acid aspartyl protease essential for viral maturation. It cleaves the Gag and Gag-Pol polyproteins into functional structural (MA, CA, NC, p6) and enzymatic (RT, IN, PR) proteins.
Mechanism
- Dimeric enzyme; active site Asp25-Thr26-Gly27.
- Cleaves >10 specific sites in polyproteins during/after budding.
- Without PR: immature, non-infectious virions.
Protease Inhibitors (PIs) — Drug Class Evolution
| Generation | Agents | Key Features |
|---|---|---|
| 1st | Saquinavir, Indinavir, Ritonavir, Nelfinavir | High pill burden, toxicity (lipodystrophy, GI), moderate resistance barrier |
| 2nd | Lopinavir/r, Atazanavir/r, Fosamprenavir/r | Boosted with ritonavir; better PK, once-daily options |
| 3rd / Boosted | Darunavir/r, Darunavir/cobicistat, Atazanavir/cobi | High genetic barrier, broad resistance coverage, preferred for treatment-experienced |
Clinical Impact
- PIs + 2 NRTIs = standard HAART backbone (1996–).
- Transformed HIV from fatal to chronic manageable condition.
- Resistance: Major mutations (D30N, V82A, I84V, L90M) reduce susceptibility; darunavir retains activity against many PI-resistant strains.
Current Guidelines
Integrase inhibitors (bictegravir, dolutegravir) now preferred first-line; PIs reserved for resistance, pregnancy (ATV/r, DRV/r), or specific scenarios.
HIV & AIDS - Related Articles
- Understanding Your Rights: Addressing HIV-Related Discrimination
- HIV Transmission Timeline: Infection Occurs in Minutes, Symptoms in Weeks
- Rights and Safety When Caring for HIV-Positive Nursing Home Residents
- Geckos and HIV: No Medicinal Value—Dangerous Myth
- HIV Transmission via Oral Sex: Risks, Prevention & Other STIs
- Treatment as Prevention (TasP) for HIV: U=U Explained
- HIV Testing: Turnaround Times by Test Type and What to Expect
